Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

P791: Activation of the aryl hydrocarbon receptor after simvastatin and recombinant antagonist of receptors of interleukin-1 treatment in a rat model of inflammatory bowel diseaseECCO '17 Barcelona

Year: 2017

Authors:

Kamyshnyi A., Kamyshna V., Kozachuk A.

Zaporozhye State Medical University, Zaporozhye, Ukraine

P792: Modulation of the fecal metagenome in patients with Crohn's diseaseECCO '17 Barcelona

Year: 2017

Authors:

Rojas-Feria M.^*1, Fernández Caballero-Rico J.A.², Pastor Ramírez H.³, Castro-Fernandez M.¹, Chueca Porcuna N.², Grande Santamaría L.¹, Romero-Gόmez M.³, García F.², Del Campo J.A.¹

¹Valme Hospital, UGC Digestive Disease, Seville, Spain ²Complejo Hospitalario Universitario de Granada, Microbiology, Granada, Spain ³Institute of Biomedicine of Seville, UG IC Digestive Diseases Virgen Macarena-Virgen Rocío, Seville, Spain

P793: Microbial composition in IBD may influence clinical symptoms independent of endoscopic activityECCO '17 Barcelona

Year: 2017

Authors:

Boland K., Turpin W., Mohammadi A., Borowski K., Kabakchiev B., Smith M.I., Nguyen G., Steinhart A.H., Croitoru K., Silverberg M.

Mount Sinai Hospital, Zane Cohen Center for Digestive Diseases, Toronto, Canada

P794: Alterations of intestinal microbiota in ulcerative colitisECCO '17 Barcelona

Year: 2017

Authors:

Danilova N.¹, Abdulkhakov S.^1,2, Grigoryeva T.^*2, Dubinkina V.³, Odintsova V.⁴, Tyakht A.^3,4, Pavlenko A.⁴, Odintsova A.², Abdulkhakov R.¹, Govorun V.⁴

¹Kazan State Medical University, Kazan, Russian Federation ²Kazan Federal University, Kazan, Russian Federation ³Moscow Institute of Physics and Technology, Moscow, Russian Federation ⁴Federal Research Centre of Physical-Chemical Medicine, Moscow, Russian Federation

DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn’s disease patientsECCO '16 Amsterdam

Year: 2016

Authors:

K. M. Taylor*^{1, 2}, N.S. Taylor³, S. H. Anderson¹, P. M. Irving¹, N. J. Prescott², C. M. Lewis², C. G. Mathew², J. D. Sanderson¹

¹Guy’s & St Thomas’ NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, ²King’s College London, Department of Medical & Molecular Genetics, London, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, United Kingdom

DOP002: Molecular response to ustekinumab in moderate-to-severe Crohn’s disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studiesECCO '16 Amsterdam

Year: 2016

Authors:

K. Li*, K. Hayden, E. Wadman, S. Bhagat, S. Emrich, J. R. Friedman, C. Gasink, C. Brodmerkel

Janssen R & D, LLC, Spring House, Pennsylvania, United States

DOP003: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

K. Li*¹, J. Ouahed², J. Friedman¹, R. Strauss¹, D. Chan¹, S. Telesco¹, D. Shouval³, J. Canavan⁴, C. Brodmerkel¹, S. Snapper⁵

¹Janssen R & D, LLC, Spring House, Pennsylvania, United States, ²Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, United States, ³Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, United States, ⁴Harvard Medical School/Brigham & Women’s Hospital, Boston, Massachusetts, United States, ⁵Boston Children’s Hospital/Harvard Medical School/Brigham & Women’s Hospital, Boston, Massachusetts United States

DOP004: Epigenetic control of colonic epithelial antigen processing, barrier function, and the microbiome via methyl-CpG binding domain protein 2ECCO '16 Amsterdam

Year: 2016

Authors:

G.-R. Jones*¹, A. MacDonald², P. Cook²

¹University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ²University of Manchester, Department of Immunology, Manchester, United Kingdom

DOP005: A role for IL1 in mediating intestinal inflammation in IL10 receptor deficiency in mice and humansECCO '16 Amsterdam

Year: 2016

Authors:

D. Shouval*^{1, 2}, A. Biswas², Y.-H. Kang², A. Griffith², B. Horwitz², A. Bousvaros², S. Snapper²

¹Safra Children’s Hospital, Paediatric Gastroenterology, Tel Hashomer, Israel, ²Boston Children’s Hospital, Boston, Massachusetts, United States

DOP006: Gut-homing adipose tissue T-cells might influence intestinal barrier function in Crohn’s disease and obesityECCO '16 Amsterdam

Year: 2016

Authors:

L. J. Jödicke*¹, L. I. Kredel¹, A. A. Kuehl¹, I. Freise¹, J. Gröne², J. Ordemann³, B. Siegmund¹

¹Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Gastroenterology, Infectiology and Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, General, Vascular and Thoracic Surgery, Berlin, Germany, ³Charité, Campus Mitte, Centre for Obesity and Metabolic Surgery, Berlin, Germany

DOP007: Interleukin-10 inhibits human IFNγ and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell functionECCO '16 Amsterdam

Year: 2016

Authors:

S. Veenbergen*¹, P. Li², H. Raatgeep¹, D. Lindenbergh-Kortleve¹, L. de Ruiter¹, M. van Leeuwen¹, D. Winter³, Y. Simons-Oosterhuis¹, L. van Berkel¹, S. Nugteren¹, J. Arnold¹, Y. Wakabayashi⁴, J. Zhu⁴, L. de Ridder³, G. Driessen⁵, J. Escher³, W. Leonard², J. Samsom¹

¹Erasmus University Medical Centre, Laboratory of Paediatrics, division Gastroenterology and Nutrition, Rotterdam, Netherlands, ²National Heart, Lung and Blood Institute, National Institutes of Health, Laboratory of Molecular Immunology, Bethesda, Maryland, United States, ³Sophia Children’s Hospital-Erasmus Medical Centre, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ⁴National Heart, Lung and Blood Institute, National Institutes of Health, DNA Sequencing and Genomics Core, Bethesda, Maryland, United States, ⁵Erasmus University Medical Centre, Department of Paediatric Infectious Disease and Immunology, Rotterdam, Netherlands

DOP008: Human intestinal Vδ2+ T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapyECCO '16 Amsterdam

Year: 2016

Authors:

C. Tyler¹, N. McCarthy*², B. Moser¹, A. Stagg², M. Eberl¹, J. Lindsay^{2, 3}

¹Cardiff University, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff, United Kingdom, ²Barts and The London School of Medicine and Dentistry, Queen Mary University of London, The Blizard Institute, Centre for Immunobiology, London, United Kingdom, ³Barts Health NHS Trust, Department of Gastroenterology, Barts and The London Hospitals, London, United Kingdom

DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitisECCO '16 Amsterdam

Year: 2016

Authors:

M. Spalinger*¹, S. Kasper¹, C. Gottier¹, S. Lang¹, M. Fried^{1, 2}, G. Rogler^{1, 2}, M. Scharl^{1, 2}

¹University Hospital Zürich, Division of Gastroenterology and Hepatology, Zürich, Switzerland, ²University of Zürich, Zürich Centre for Integrative Human Physiology, Zürich, Switzerland

DOP010: Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from a Central European nationwide cohortECCO '16 Amsterdam

Year: 2016

Authors:

A. Bálint*¹, K. Farkas¹, M. Rutka¹, Z. Végh², Z. Kürti³, J. Banai⁴, L. Bene⁵, B. Gasztonyi⁶, T. Kristóf⁷, L. Lakatos⁸, P. Miheller⁹, K. Palatka¹⁰, A. Patai¹¹, A. Salamon¹², T. Szamosi⁴, Z. Szepes¹, G.T. Tóth¹³, A. Vincze¹⁴, R. Bor¹, A. Milassin¹, F. Nagy¹, M. Kolar^{15, 16}, M. Bortlik^{15, 17}, D. Duricova^{15, 18}, V. Hruba¹⁵, M. Lukas¹⁵, K. Mitrova^{15, 19}, K. Malickova²⁰, M. Lukas^{15, 20}, P.L. Lakatos², T. Molnár¹

¹University of Szeged, First Department of Medicine, Szeged, Hungary, ²Semmelweis University, First Department of Medicine, Budapest, Hungary, ³Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, ⁴Military Hospital – State Health Centre, Budapest, Hungary, ⁵Peterfy Hospital, First Department of Medicine, Budapest, Hungary, ⁶Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, ⁷B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, ⁸Csolnoky Ferenc Regional Hospital, Department of Internal Medicine, Veszprem, Hungary, ⁹Semmelweis University, Second Department of Internal Medicine, Budapest, Hungary, ¹⁰University of Debrecen, Second Department of Medicine, Debrecen, Hungary, ¹¹Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹²Tolna County Teaching Hospital, Department of Gastroenterology, Szekszard, Hungary, ¹³Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁴University of Pécs, First Department of Medicine, Pécs, Hungary, ¹⁵IBD Clinical and Research Centre, Iscare a.s, Prague, Czech Republic, ¹⁶Charles University, First Medical Faculty, Prague, Czech Republic, ¹⁷Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, ¹⁸First Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, ¹⁹Faculty Hospital Motol, Second Medical Faculty, Charles University, Department of Paediatrics, Prague, Czech Republic, ²⁰First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

DOP011: Early immunomodulator exposure and the long-term outcome of Crohn’s disease: target for changing the natural historyECCO '16 Amsterdam

Year: 2016

Authors:

S. Jeuring*^{1, 2}, D. Wintjens¹, A. Wesselius³, T. Van den Heuvel^{1, 2},  M. Zeegers^{3, 4}, W. Hameeteman¹, M. Romberg-Camps⁵, L. Oostenbrug⁶, A. Masclee^{1, 2}, D. Jonkers^{1, 2}, M. Pierik^{1, 2}

¹Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, ⁴Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, ⁵Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, ⁶Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands

DOP012: Do ulcerative colitis patients treated with corticosteroids at diagnosis really have a more aggressive disease course?ECCO '16 Amsterdam

Year: 2016

Authors:

L. Bertani*¹, N. de Bortoli¹, G. Bodini², G. Mumolo³, L. Ceccarelli⁴, M. C. Plaz Torres², G. Laino¹, M. Bellini³, A. Ricchiuti³, V. Savarino², S. Marchi¹, F. Costa³

¹University of Pisa, Department of Gastroenterology, Pisa, Italy, ²University of Genoa, Department of Gastroenterology, Genoa, Italy, ³Pisa University Hospital, Department of Gastroenterology, Pisa, Italy, ⁴SSD Endoscopy ASL 1, Massa, Italy

DOP013: A 104 week mucosal healing assessment of symptomatic small bowel Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

B. Hall*¹, G. Holleran¹, L. Chapman¹, B. Ryan¹, N. Mahmud², D. McNamara¹

¹Adelaide & Meath Hospital, Dublin, Incorporating The National Children’s Hospital, Department of Gastroenterology, Dublin, Ireland, ²Trinity College Dublin, St James Hospital, Department of Gastroenterology, Dublin, Ireland

DOP014: Nutritional optimisation of presurgical Crohn’s disease patients with enteral nutrition significantly decreases length of stay and need for a stomaECCO '16 Amsterdam

Year: 2016

Authors:

K. V. Patel*¹, A. M. Sandall², D. V. O’Hanlon³, A. A. Darakhshan⁴, A. B. Williams⁴, S. H. Anderson¹, P. M. Irving¹, M. C. Lomer⁵, J. D. Sanderson¹

¹Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, ²King’s College London, Diabetes and Nutritional Sciences Division, London, United Kingdom, ³Guy’s and St Thomas’ NHS Foundation Trust, Dietetics, London, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, Colorectal Surgery, London, United Kingdom, ⁵King’s College London, Diabetes and Nutritional Sciences Division, London, United Kingdom

DOP015: Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

S. Decousus¹, A.-L. Boucher², J. Joubert¹, M. Goutte^{2, 3}, F. Goutorbe², A. Dubois⁴, B. Pereira⁵, P. Dechelotte¹, G. Bommelaer^{2, 3}, A. Buisson*^{2, 3}

¹University Hospital Estaing, Pathology Department, Clermont-Ferrand, France, ²University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, ³UMR 1071 Inserm/Université d’Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, ⁴CHU Estaing, Department of Digestive surgery, Clermont-Ferrand, France, ⁵GM – Clermont-Ferrand University and Medical Centre, Biostatistics Unit, Clermont-Ferrand, France

DOP016: Postoperative clinical recurrence is not different in Crohn’s disease patients classified as i2 on the Rutgeerts score with lesions confined to the ileocolonic anastomosis than in those with lesions of the neoterminal ileumECCO '16 Amsterdam

Year: 2016

Authors:

P. Bayart*¹, N. Duveau¹, M. Nachury¹, P. Zerbib¹, R. Gerard¹, J. Branche¹, V. Maunoury¹, A. Boruchowicz², M. Boualit², J.-E. Laberenne³, O. Manolache³, G. Pineton de Chambrun⁴, B. Pariente¹

¹CHRU de Lille, Lille, France, ²CH Valenciennes, Valenciennes, France, ³CH Seclin, Seclin, France, ⁴CHU Montpellier, Montpellier, France